1 day Ago By ABMN Staff
Ocugen ( NASDAQ:OCGN – Get Free Report ) ‘s stock had its “buy” rating reissued by Chardan Capital in a note issued to investors on Monday, Benzinga reports. They presently have a $6.00 price objective on the stock.
A number of other equities analysts have also weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Ocugen in a research note on Monday, November 11th.
Maxim Group initiated coverage on shares of Ocugen in a research note on Tuesday, October 15th. They issued a “buy” rating and a $4.00 target price for the company.
Check Out Our Latest Analysis on OCGN Ocugen Price Performance Hedge Funds Weigh In On Ocugen A number of large investors have recently modified their holdings of the business. Barclays PLC boosted its stake in shares of Ocugen by 104.3% during the 3rd quarter.
Barclays PLC now owns 581,087 shares of the company’s stock worth $577,000 after buying an additional 296,654 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Ocugen by 6.3% during the 3rd quarter.
Geode Capital Management LLC now owns 6,278,554 shares of the company’s stock worth $6,231,000 after buying an additional 373,555 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Ocugen during the 3rd quarter worth about $233,000. Wellington Management Group LLP acquired a new position in shares of Ocugen during the 3rd quarter worth about $456,000.
Finally, State Street Corp boosted its stake in shares of Ocugen by 7.1% during the 3rd quarter. State Street Corp now owns 15,824,517 shares of the company’s stock worth $15,701,000 after buying an additional 1,047,896 shares during the last quarter.
10.27% of the stock is currently owned by institutional investors and hedge funds. About Ocugen ( Get Free Report ) Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health.
The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. Featured Articles Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter .
.
